×
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

C Reactive Protein Testing Market Analysis

ID: MRFR/LS/10636-HCR
128 Pages
Rahul Gotadki
October 2025

C reactive protein testing Market Research Report Information By Assay Type (Enzyme-linked Immunosorbent Assay (ELISA), Chemiluminescence Immunoassay (CLIA), Immunoturbidimetric Assays, and Others), By Application (Diabetes, Rheumatoid Arthritis, Cardiovascular Disease, Inflammatory Bowel Disease, and Others) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

C Reactive Protein Testing Market Infographic
Request Free Sample
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

Market Analysis

In-depth Analysis of C Reactive Protein Testing Market Industry Landscape

The global C reactive protein testing market is set to reach US$ 3.82 BN by 2032, at a 6.90% CAGR between years 2023-2032. The dynamics of the market for CRP are driven by heightened awareness of CRP as a complex and emerging biomarker in inflammatory disease detection. The Malaria drug is being widely used with an increasing number of users, which may be the market driving factor for this industry. The necessity of early-onset detection of these disorders combined with the implementation of treatment to minimize progression has risen sharply, consequently requiring an increase in CRP testing for diagnostic purposes and as a disease marker activity tool. This makes technological advancements one of the many drivers that contribute to the determination of the market for CRP testing dynamics. New developments in the assay technologies, with specific regard to high-sensitivity CRP (hs-CRP) assays, assure further increasing of the accuracy and sensitivity of CRP determination. Such developments improve the effectiveness of CRP testing under both conditions – acute and chronic inflammatory in so far as increased understanding of therapeutic aspects is concerned, they equip clinical personnel with useful information for risk assessment and treatment decisions. CRP testing into routine clinical practice centres around physicians, clinical laboratorians, and hospitals. Physicians order the tests; when positive for inflammation they often seek inputs from a pathologist via a clinician lab physician as to whether to consider ordering specialty associated (e.g., myeloid histiocytic) subtype tests e.g., FISH molecular. The use of CRP testing is utilized across different branches in medical practice from cardiology, rheumatology, infectious diseases to nonspecific medicine. The transition towards individualized and evidence-driven medicine reinforces the significance of CRP testing to guide and develop therapeutic strategies based on a metainformation level of an individual patient. Never-the-less issues of regulation are the most crucial element in CRP testing market. Due to the interstate character of CRP assays and formal inhibitors that are required for them their development, production process regulations, and permission on the market stringent regulatory framework’s function. In the market these entities significantly govern product design, ensure quality assurance, and approve strategies of how they will enter the given market. Market drivers are economic factors that play an essential role in dynamizing the market, which includes healthcare expenditure and reimbursement policies, and cost-effectiveness. Theories which influence accessibility of CRP testing include affordability as well as reimbursement policies. In view of economic considerations, CRP testing embraces a higher adoption rate and market penetration in clinical settings. The International organizations and collaborative programs engaged in developing biomarkers for inflammatory disease such as CRP drives the market growth. The joint efforts between companies and the centers of research, tests diagnosis as well as practice clinics are aimed at enhancing equal understanding about how CRP contributes to various conditions and how performance in testing terrain may be improved to develop new methods. This cooperation adds to the collective body of information and stimulates therein innovation for CRP testing technologies.

Author
Rahul Gotadki
Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Get In Touch

Leave a Comment

FAQs

What is the current valuation of the C-Reactive Protein Testing Market?

The C-Reactive Protein Testing Market was valued at 3.196 USD Billion in 2024.

What is the projected market size for the C-Reactive Protein Testing Market by 2035?

The market is projected to reach 6.66 USD Billion by 2035.

What is the expected CAGR for the C-Reactive Protein Testing Market during the forecast period?

The expected CAGR for the market from 2025 to 2035 is 6.9%.

Which assay type segment shows the highest growth potential in the market?

The Chemiluminescence immunoassay (CLIA) segment is projected to grow from 1.0 to 2.0 USD Billion.

How does the market for C-Reactive Protein Testing relate to cardiovascular disease?

The market for C-Reactive Protein Testing in cardiovascular disease applications was valued at 1.278 USD Billion in 2024 and is expected to grow significantly.

Who are the key players in the C-Reactive Protein Testing Market?

Key players include Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, and Thermo Fisher Scientific.

Market Summary

As per MRFR analysis, the C-Reactive Protein Testing Market was estimated at 3.196 USD Billion in 2024. The C-Reactive Protein Testing industry is projected to grow from 3.417 USD Billion in 2025 to 6.66 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 6.9% during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The C-Reactive Protein Testing Market is experiencing robust growth driven by technological advancements and increasing awareness of inflammatory diseases.

  • Technological advancements in testing methodologies are enhancing the accuracy and efficiency of C-Reactive Protein tests. North America remains the largest market, while Asia-Pacific is emerging as the fastest-growing region for C-Reactive Protein testing. The Chemiluminescence Immunoassay segment dominates the market, whereas the Enzyme-linked Immunosorbent Assay segment is witnessing rapid growth. Rising incidence of chronic diseases and increased focus on preventive healthcare are key drivers propelling market expansion.

Market Size & Forecast

2024 Market Size 3.196 (USD Billion)
2035 Market Size 6.66 (USD Billion)
CAGR (2025 - 2035) 6.9%
Largest Regional Market Share in 2024 North America

Major Players

<p><a href="https://diagnostics.roche.com/global/en/products/lab/crphs-cps-000086.html">Roche Diagnostics</a> (CH), Abbott Laboratories (US), Siemens Healthineers (DE), Thermo Fisher Scientific (US), Ortho Clinical Diagnostics (US), Beckman Coulter (US), QuidelOrtho Corporation (US), Bio-Rad Laboratories (US)</p>

Market Trends

The C-Reactive Protein Testing Market is currently experiencing notable developments driven by an increasing awareness of chronic diseases and the importance of early diagnosis. Healthcare professionals are increasingly recognizing the role of C-Reactive Protein (CRP) as a biomarker for inflammation, which is linked to various conditions such as cardiovascular diseases and autoimmune disorders. This growing understanding is likely to enhance the demand for CRP testing, as it provides valuable insights into a patient's health status. Furthermore, advancements in testing technologies, including point-of-care testing and high-sensitivity assays, are expected to improve accessibility and convenience for both patients and healthcare providers. In addition, the C-Reactive Protein Testing Market is influenced by the rising prevalence of lifestyle-related diseases, which necessitates regular monitoring of inflammatory markers. As populations age and the burden of chronic illnesses increases, the need for effective diagnostic tools becomes more pronounced. The integration of CRP testing into routine health check-ups may become more commonplace, reflecting a shift towards preventive healthcare. Overall, the market appears poised for growth, driven by technological innovations and a heightened focus on health management strategies that prioritize early detection and intervention.

Technological Advancements in Testing

Recent innovations in testing methodologies are transforming the C-Reactive Protein Testing Market. The introduction of high-sensitivity assays and point-of-care testing devices enhances the accuracy and speed of results, making it easier for healthcare providers to make informed decisions. These advancements may lead to increased adoption rates among clinicians and patients alike.

Growing Awareness of Inflammatory Diseases

There is a rising awareness regarding the impact of inflammation on health, which is likely to drive demand for CRP testing. As more individuals become informed about the link between inflammation and chronic diseases, the market may see an uptick in testing as part of routine health assessments. This trend suggests a shift towards proactive health management.

Integration into Preventive Healthcare

The C-Reactive Protein Testing Market is witnessing a trend towards integration into preventive healthcare practices. As healthcare systems emphasize early detection and management of diseases, CRP testing may become a standard component of health screenings. This shift could enhance patient outcomes and reduce long-term healthcare costs.

C Reactive Protein Testing Market Market Drivers

Rising Incidence of Chronic Diseases

The increasing prevalence of chronic diseases such as cardiovascular disorders and diabetes is a notable driver for the C-Reactive Protein Testing Market. As these conditions are often associated with elevated levels of C-Reactive Protein (CRP), healthcare providers are increasingly utilizing CRP testing as a diagnostic tool. According to recent data, the incidence of chronic diseases has been on the rise, leading to a heightened demand for effective monitoring and management strategies. This trend suggests that the C-Reactive Protein Testing Market is likely to experience growth as healthcare systems prioritize early detection and intervention. Furthermore, the integration of CRP testing into routine health assessments may enhance patient outcomes, thereby reinforcing the market's expansion.

Advancements in Diagnostic Technologies

Technological innovations in diagnostic testing are significantly influencing the C-Reactive Protein Testing Market. The development of high-sensitivity CRP assays has improved the accuracy and reliability of CRP measurements, making them more accessible for clinical use. These advancements enable healthcare professionals to better assess inflammation levels and associated risks. Moreover, the introduction of point-of-care testing devices allows for rapid results, facilitating timely clinical decisions. As a result, the market is witnessing an increase in the adoption of these advanced testing methods, which could potentially lead to a broader application of CRP testing in various healthcare settings. The ongoing research and development in this field may further enhance the capabilities of CRP testing, thereby driving market growth.

Increased Focus on Preventive Healthcare

The growing emphasis on preventive healthcare is a significant factor propelling the C-Reactive Protein Testing Market. As healthcare systems shift towards proactive management of health, CRP testing is being recognized for its role in identifying individuals at risk of developing chronic inflammatory conditions. This preventive approach aligns with global health initiatives aimed at reducing the burden of diseases. Data indicates that healthcare expenditures on preventive measures are increasing, which may lead to a higher demand for CRP testing as part of routine health screenings. Consequently, the C-Reactive Protein Testing Market is likely to benefit from this trend, as more individuals seek early detection and management of potential health issues.

Regulatory Support for Diagnostic Testing

Regulatory bodies are increasingly recognizing the importance of diagnostic testing, including C-Reactive Protein Testing, in clinical practice. This support is evident in the streamlined approval processes for new testing technologies and the establishment of guidelines that promote the use of CRP testing in various healthcare settings. Such regulatory frameworks are likely to enhance the credibility and adoption of CRP testing among healthcare providers. Furthermore, as regulations evolve to support innovative diagnostic solutions, the C-Reactive Protein Testing Market may experience accelerated growth. The alignment of regulatory policies with advancements in testing methodologies could foster a more robust market environment, encouraging investment and development in CRP testing solutions.

Growing Research in Inflammatory Biomarkers

The expanding body of research focused on inflammatory biomarkers is contributing to the growth of the C-Reactive Protein Testing Market. As scientists and clinicians explore the relationship between inflammation and various diseases, CRP has emerged as a key biomarker for assessing inflammatory responses. This research is not only enhancing the understanding of disease mechanisms but also promoting the clinical utility of CRP testing in diverse medical fields. The increasing number of studies published on CRP and its implications in health may lead to greater acceptance and utilization of CRP testing in clinical practice. This trend suggests a promising future for the C-Reactive Protein Testing Market as it aligns with the evolving landscape of personalized medicine.

Market Segment Insights

By Assay Type: Chemiluminescence Immunoassay (Largest) vs. Enzyme-linked Immunosorbent Assay (Fastest-Growing)

<p>In the C-Reactive Protein Testing Market, the <a href="https://www.marketresearchfuture.com/reports/chemiluminescence-immunoassay-market-43371">Chemiluminescence Immunoassay (CLIA)</a> accounts for the largest segment share, reflecting its widespread adoption due to sensitivity and rapid results. Following closely, the Enzyme-linked Immunosorbent Assay (ELISA) is also significant, known for its robustness in different settings. Other methods such as immunoturbidimetric assays make up a smaller portion of the market, but they cater to specific testing needs. This diverse distribution is essential as different assay types serve various applications, from clinical laboratories to point-of-care settings. In terms of growth trends, the ELISA segment is currently experiencing a rapid rise in adoption, primarily due to advancements in technology and increasing demand for precise and efficient testing methods. Market drivers also include the rising prevalence of chronic diseases and ongoing research initiatives focusing on inflammatory markers. There is a notable shift towards automated systems and point-of-care testing, which further augments the market for specific assay types, particularly the ELISA, which is becoming more integrated into routine diagnostics.</p>

<p>Chemiluminescence Immunoassay (Dominant) vs. Enzyme-linked Immunosorbent Assay (Emerging)</p>

<p>The Chemiluminescence Immunoassay (CLIA) continues to dominate the C-Reactive Protein Testing Market due to its high sensitivity and ability to deliver results quickly. This method leverages the properties of light-emitting reactions to detect the presence of CRP in samples, making it prevalent in both clinical and research environments. Conversely, the Enzyme-linked Immunosorbent Assay (ELISA) is emerging as a pivotal player, driven by recent technological advancements that enhance its accuracy and efficiency. While historically it has been regarded as a standard method, its rejuvenation offers significant potential for growth, especially in point-of-care testing scenarios. Both assay types are crucial for addressing the escalating demand for reliable and timely CRP testing across diverse healthcare settings.</p>

By Application: Cardiovascular Disease (Largest) vs. Rheumatoid Arthritis (Fastest-Growing)

<p>In the C-Reactive Protein Testing Market, the application segment reveals that Cardiovascular Disease holds the largest share, primarily driven by rising prevalence and increased awareness of heart-related conditions. This application significantly influences overall market dynamics due to its critical role in indicating cardiovascular inflammation, thus supporting diagnostic and therapeutic strategies. Following closely is the Rheumatoid Arthritis segment, recognized as the fastest-growing category, owing to heightened incidences and better diagnostic capabilities. The awareness and validation of CRP testing as a reliable marker for arthritic conditions propel this segment forward as healthcare providers look for effective monitoring and management techniques.</p>

<p>Cardiovascular Disease (Dominant) vs. Rheumatoid Arthritis (Emerging)</p>

<p>Cardiovascular Disease is characterized by its substantial market demand, being a primary focus in the healthcare sector due to its correlation with severe health outcomes. This segment thrives on established protocols that incorporate C-Reactive Protein testing to monitor inflammation, which serves as a crucial marker for predicting cardiovascular events. In contrast, Rheumatoid Arthritis is emerging rapidly, driven by advancements in testing technologies and increasing rates of diagnosis. The rising awareness surrounding autoimmune conditions has led to a surge in the adoption of CRP testing, positioning it as a key player in disease management. This dynamic growth is further supported by ongoing research that reinforces the validity of CRP as a biomarker for treatment efficacy.</p>

Get more detailed insights about C Reactive Protein Testing Market Research Report 2035

Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American C-Reactive protein testing market will dominate this market, with an increase in the adoption of cutting-edge technology and a significant focus on clinical research in North America. Given how prevalent cancer is in the United States, CRP testing is often employed.

Further, the major countries studied in the market report are The US, Canada, German, Italy, Spain, China, Japan, France, the UK, India, Australia, South Korea, and Brazil.

Figure 2: C REACTIVE PROTEIN TESTING MARKET SHARE BY REGION 2022 (USD Billion) 

Europe has the second-largest market share for C-reactive protein testing. The prevalence of a well-established healthcare infrastructure, rising rates of CVD, rheumatoid arthritis, and other inflammatory diseases, and a favorable reimbursement environment. Furthermore, the German market of C reactive protein testing dominated, while the UK market of C reactive protein testing grew fastest in Europe.

From 2023 to 2032, the Asia-Pacific C reactive protein testing Market will develop at the quickest CAGR. An increase in hospitals and a rise in hospital admissions for emergency treatment are driving the market's expansion in this area. A key factor driving market development is the rise in traffic accidents, which raises the patient population. Furthermore, China's market of C reactive protein testing had the highest market share. In contrast, the Asia-Pacific region's market of C reactive protein testing in India was the one that was growing the quickest.

Key Players and Competitive Insights

Leading market companies are extensively spending R&D on increasing their product lines, which will help the market of C reactive protein testing grow even more. Important market developments include new product releases, contractual agreements, acquisitions and mergers, greater investments, and collaboration with other organizations. The C reactive protein testing industry must produce cost-effective merchandise to flourish and thrive in a more competitive and increasing market climate.

Manufacturing locally to reduce operating costs is an effective business strategy manufacturers use in the worldwide C reactive protein testing industry to serve clients and expand the market sector. The C reactive protein testing industry has provided some of the most important benefits recently. LumiraDx, Trivitron Healthcare's, and other major competitors in the market of C reactive protein testing are seeking to improve market demand by investing in R&D efforts.

A next-generation point-of-care diagnostics business called LumiraDx is revolutionizing community-based healthcare. Since its establishment in 2014, LumiraDx has produced and sold a revolutionary diagnostic Platform that enables a wide range of tests with point-of-care performance that is on par with a lab's. 

Governments and top healthcare organizations use LumiraDx diagnostic testing systems in clinics, urgent care centers, doctor's offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness and illness. On the LumiraDx Platform, LumiraDx offers more than 30 tests for infectious illnesses, cardiovascular diseases, diabetes, and coagulation disorders available or under development. 

Additionally, LumiraDx offers a wide range of quick, precise, and reasonably priced COVID-19 testing options from the lab to the point of need. In January 2022, LumiraDx announced the C-reactive protein (CRP) Test CE Marking. The LumiraDx CRP Test measures C-reactive protein quantitatively and provides findings in four minutes. It is a tiny, portable, fully automated microfluidic immunoassay test. CRP testing offers crucial information to diagnose and assess infection and inflammation.

Trivitron Healthcare's history as a medical technology firm offering cost-effective solutions has been a fascinating source of inspiration for many healthcare professionals since 1997. Hospitals, private healthcare practitioners, independent clinics and laboratories, long-term care facilities, renal care centers, and other structures offering healthcare solutions are the target markets for Trivitron's goods. Trivitron, a leader in the industry, is continually looking for new technical advancements to provide better clinical advantages at a reduced price. 

In June 2021, In order to simplify COVID-19 diagnosis in remote, urban, and rural areas of India, Trivitron Healthcare created a mobile laboratory. The local lab offers RT-PCR assays, fast antigen tests, CLIA/Elisa IgG and IgM antibody tests, and CLIA/Elisa tests for inflammatory indicators, including D-Dimer, CRP and IL-6.

Key Companies in the C Reactive Protein Testing Market market include

Industry Developments

  • Q2 2024: C-reactive protein testing: Powering precision in inflammation and cardiovascular diagnostics In 2024, the C-reactive protein (CRP) testing market saw a surge in direct-to-home testing services, with new CRP testing kits designed for at-home use expanding access to diagnostics for patients managing long-term health conditions or residing in remote areas.

Future Outlook

C Reactive Protein Testing Market Future Outlook

<p>The C-Reactive Protein Testing Market is projected to grow at a 6.9% CAGR from 2024 to 2035, driven by increasing chronic disease prevalence and advancements in diagnostic technologies.</p>

New opportunities lie in:

  • <p>Development of point-of-care testing devices for rapid results</p>
  • <p>Integration of AI for enhanced data analysis and patient management</p>
  • <p>Expansion into emerging markets with tailored diagnostic solutions</p>

<p>By 2035, the market is expected to achieve substantial growth, reflecting evolving healthcare demands.</p>

Market Segmentation

C Reactive Protein Testing Market Assay Type Outlook

  • Enzyme-linked immunosorbent assay (ELISA)
  • Chemiluminescence immunoassay (CLIA)
  • Immunoturbidimetric assays
  • Others

C Reactive Protein Testing Market Application Outlook

  • Diabetes
  • Rheumatoid Arthritis
  • Cardiovascular Disease
  • Inflammatory Bowel Disease
  • Others

Report Scope

MARKET SIZE 2024 3.196(USD Billion)
MARKET SIZE 2025 3.417(USD Billion)
MARKET SIZE 2035 6.66(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR) 6.9% (2024 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Billion
Key Companies Profiled Market analysis in progress
Segments Covered Market segmentation analysis in progress
Key Market Opportunities Integration of advanced diagnostic technologies enhances accuracy in the C-Reactive Protein Testing Market.
Key Market Dynamics Rising demand for rapid diagnostic solutions drives innovation and competition in the C-Reactive Protein Testing market.
Countries Covered North America, Europe, APAC, South America, MEA

FAQs

What is the current valuation of the C-Reactive Protein Testing Market?

The C-Reactive Protein Testing Market was valued at 3.196 USD Billion in 2024.

What is the projected market size for the C-Reactive Protein Testing Market by 2035?

The market is projected to reach 6.66 USD Billion by 2035.

What is the expected CAGR for the C-Reactive Protein Testing Market during the forecast period?

The expected CAGR for the market from 2025 to 2035 is 6.9%.

Which assay type segment shows the highest growth potential in the market?

The Chemiluminescence immunoassay (CLIA) segment is projected to grow from 1.0 to 2.0 USD Billion.

How does the market for C-Reactive Protein Testing relate to cardiovascular disease?

The market for C-Reactive Protein Testing in cardiovascular disease applications was valued at 1.278 USD Billion in 2024 and is expected to grow significantly.

Who are the key players in the C-Reactive Protein Testing Market?

Key players include Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, and Thermo Fisher Scientific.

  1. Executive summary
  2. Market Introduction
    1. Definition
    2. Scope of the Study
      1. Research Objective
      2. Assumptions
      3. Limitations
  3. Research Methodology
    1. Overview
    2. Data Mining
    3. Secondary Research
    4. Primary Research
      1. Primary Interviews and Information Gathering Process
      2. Breakdown of Primary Respondents
    5. Forecasting Model
    6. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
    7. Data Triangulation
    8. Validation
  4. Market Dynamics
    1. Overview
    2. Drivers
    3. Restraints
    4. Opportunities
  5. Market Factor Analysis
    1. Value Chain Analysis
    2. Porter’s Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of New Entrants
      4. Threat of Substitutes
      5. Intensity of Rivalry
    3. COVID-19 Impact Analysis
      1. Market Impact Analysis
      2. Regional Impact
      3. Opportunity and Threat Analysis
  6. GLOBAL C REACTIVE PROTEIN TESTING MARKET, BY Assay Type
    1. Overview
    2. Enzyme-linked immunosorbent assay (ELISA)
    3. Chemiluminescence Immunoassay (CLIA)
    4. Immunoturbidimetric assays
  7. GLOBAL C REACTIVE PROTEIN TESTING MARKET, BY Application
    1. Diabetes
    2. Rheumatoid Arthritis
    3. Cardiovascular Disease
    4. Inflammatory Bowel Disease
    5. Others
  8. GLOBAL C REACTIVE PROTEIN TESTING MARKET, by Region
    1. Overview
    2. North America
      1. US
      2. Canada
    3. Europe
      1. Germany
      2. France
      3. UK
      4. Italy
      5. Spain
      6. Rest of Europe
    4. Asia-Pacific
      1. China
      2. India
      3. Japan
      4. South Korea
      5. Australia
      6. Rest of Asia-Pacific
    5. Rest of the World
      1. Middle East
      2. Africa
      3. Latin America
  9. Competitive Landscape
    1. Overview
    2. Competitive Analysis
    3. Market Share Analysis
    4. Major Growth Strategy in the Global C reactive protein testing Market,
    5. Competitive Benchmarking
    6. Leading Players in Terms of Number of Developments in the Global C reactive protein testing Market,
    7. Key developments and Growth Strategies
      1. New Product Launch/Service Deployment
      2. Merger & Acquisitions
      3. Joint Ventures
    8. Major Players Financial Matrix
      1. Sales & Operating Income, 2022
      2. Major Players R&D Expenditure. 2022
  10. Company ProfileS
    1. Randox Laboratories Limited
      1. Company Overview
      2. Financial Overview
      3. Products Offered
      4. Key Developments
      5. SWOT Analysis
      6. Key Strategies
    2. Merck KGAA (Millipore Sigma)
      1. Company Overview
      2. Financial Overview
      3. Products Offered
      4. Key Developments
      5. SWOT Analysis
      6. Key Strategies
    3. Quest Diagnostics Incorporated
      1. Company Overview
      2. Financial Overview
      3. Products Offered
      4. Key Developments
      5. SWOT Analysis
      6. Key Strategies
    4. Abbott Laboratories
      1. Company Overview
      2. Financial Overview
      3. Products Offered
      4. Key Developments
      5. SWOT Analysis
      6. Key Strategies
    5. Zoetis Inc. (Abaxis Inc.)
      1. Company Overview
      2. Financial Overview
      3. Products Offered
      4. Key Developments
      5. SWOT Analysis
      6. Key Strategies
    6. Thermo Fisher Scientific
      1. Company Overview
      2. Financial Overview
      3. Products Offered
      4. Key Developments
      5. SWOT Analysis
      6. Key Strategies
    7. Danaher Corporation (Beckman Coulter Inc.)
      1. Company Overview
      2. Financial Overview
      3. Products Offered
      4. Key Developments
      5. SWOT Analysis
      6. Key Strategies
    8. HORIBA, LTD
      1. Company Overview
      2. Financial Overview
      3. Products Offered
      4. Key Developments
      5. SWOT Analysis
      6. Key Strategies
    9. F. Hoffmann-La Roche AG
      1. Company Overview
      2. Financial Overview
      3. Products Offered
      4. Key Developments
      5. SWOT Analysis
      6. Key Strategies
    10. Laboratory Corporation of America Holdings
      1. Company Overview
      2. Financial Overview
      3. Products Offered
      4. Key Developments
      5. SWOT Analysis
      6. Key Strategies
  11. Appendix
    1. References
    2. Related Reports LIST OF TABLES
  12. Global C reactive protein testing Market, Synopsis, 2018-2032
  13. Global C reactive protein testing Market, Estimates & Forecast, 2018-2032 (USD BILLION)
  14. GLOBAL C REACTIVE PROTEIN TESTING MARKET, BY Assay Type, 2018-2032 (USD BILLION)
  15. GLOBAL C REACTIVE PROTEIN TESTING MARKET, BY Application, 2018-2032 (USD BILLION)
  16. North America: C REACTIVE PROTEIN TESTING MARKET, BY Assay Type, 2018-2032 (USD BILLION)
  17. North America: C REACTIVE PROTEIN TESTING MARKET, BY Application, 2018-2032 (USD BILLION)
  18. US: C REACTIVE PROTEIN TESTING MARKET, BY Assay Type, 2018-2032 (USD BILLION)
  19. US: C REACTIVE PROTEIN TESTING MARKET, BY Application, 2018-2032 (USD BILLION)
  20. Canada: C REACTIVE PROTEIN TESTING MARKET, BY Assay Type, 2018-2032 (USD BILLION)
  21. Canada: C REACTIVE PROTEIN TESTING MARKET, BY Application, 2018-2032 (USD BILLION)
  22. Europe: C REACTIVE PROTEIN TESTING MARKET, BY Assay Type, 2018-2032 (USD BILLION)
  23. Europe: C REACTIVE PROTEIN TESTING MARKET, BY Application, 2018-2032 (USD BILLION)
  24. germany: C REACTIVE PROTEIN TESTING MARKET, BY Assay Type, 2018-2032 (USD BILLION)
  25. germany: C REACTIVE PROTEIN TESTING MARKET, BY Application, 2018-2032 (USD BILLION)
  26. FRANCE: C REACTIVE PROTEIN TESTING MARKET, BY Assay Type, 2018-2032 (USD BILLION)
  27. FRANCE: C REACTIVE PROTEIN TESTING MARKET, BY Application, 2018-2032 (USD BILLION)
  28. italy: C REACTIVE PROTEIN TESTING MARKET, BY Assay Type, 2018-2032 (USD BILLION)
  29. italy: C REACTIVE PROTEIN TESTING MARKET, BY Application, 2018-2032 (USD BILLION)
  30. spain: C REACTIVE PROTEIN TESTING MARKET, BY Assay Type, 2018-2032 (USD BILLION)
  31. spain: C REACTIVE PROTEIN TESTING MARKET, BY Application, 2018-2032 (USD BILLION)
  32. UK: C REACTIVE PROTEIN TESTING MARKET, BY Assay Type, 2018-2032 (USD BILLION)
  33. UK: C REACTIVE PROTEIN TESTING MARKET, BY Application, 2018-2032 (USD BILLION)
  34. rest of europe: C REACTIVE PROTEIN TESTING MARKET, BY Assay Type, 2018-2032 (USD BILLION)
  35. rest of europe: C REACTIVE PROTEIN TESTING MARKET, BY Application, 2018-2032 (USD BILLION)
  36. Asia-Pacific: C REACTIVE PROTEIN TESTING MARKET, BY Assay Type, 2018-2032 (USD BILLION)
  37. Asia-Pacific: C REACTIVE PROTEIN TESTING MARKET, BY Application, 2018-2032 (USD BILLION)
  38. japan: C REACTIVE PROTEIN TESTING MARKET, BY Assay Type, 2018-2032 (USD BILLION)
  39. japan: C REACTIVE PROTEIN TESTING MARKET, BY Application, 2018-2032 (USD BILLION)
  40. japan: C REACTIVE PROTEIN TESTING MARKET, BY End User, 2018-2032 (USD BILLION)
  41. china: C REACTIVE PROTEIN TESTING MARKET, BY Assay Type, 2018-2032 (USD BILLION)
  42. china: C REACTIVE PROTEIN TESTING MARKET, BY Application, 2018-2032 (USD BILLION)
  43. india: C REACTIVE PROTEIN TESTING MARKET, BY Assay Type, 2018-2032 (USD BILLION)
    1. TABLE 23
  44. india: C REACTIVE PROTEIN TESTING MARKET, BY Application, 2018-2032 (USD BILLION)
  45. australia: C REACTIVE PROTEIN TESTING MARKET, BY Assay Type, 2018-2032 (USD BILLION)
  46. australia: C REACTIVE PROTEIN TESTING MARKET, BY Application, 2018-2032 (USD BILLION)
  47. south korea: C REACTIVE PROTEIN TESTING MARKET, BY Assay Type, 2018-2032 (USD BILLION)
  48. south korea: C REACTIVE PROTEIN TESTING MARKET, BY Application, 2018-2032 (USD BILLION)
  49. rest of asia-pacific: C REACTIVE PROTEIN TESTING MARKET, BY Assay Type, 2018-2032 (USD BILLION)
  50. rest of asia-pacific: C REACTIVE PROTEIN TESTING MARKET, BY Application, 2018-2032 (USD BILLION)
  51. rest of the world: C REACTIVE PROTEIN TESTING MARKET, BY Assay Type, 2018-2032 (USD BILLION)
  52. rest of the world: C REACTIVE PROTEIN TESTING MARKET, BY Application, 2018-2032 (USD BILLION)
  53. Middle east: C REACTIVE PROTEIN TESTING MARKET, BY Assay Type, 2018-2032 (USD BILLION)
  54. Middle east: C REACTIVE PROTEIN TESTING MARKET, BY Application, 2018-2032 (USD BILLION)
  55. Africa: C REACTIVE PROTEIN TESTING MARKET, BY Assay Type, 2018-2032 (USD BILLION)
  56. Africa: C REACTIVE PROTEIN TESTING MARKET, BY Application, 2018-2032 (USD BILLION)
  57. Latin america: C REACTIVE PROTEIN TESTING MARKET, BY Assay Type, 2018-2032 (USD BILLION)
  58. Latin america: C REACTIVE PROTEIN TESTING MARKET, BY Application, 2018-2032 (USD BILLION) LIST OF FIGURES
  59. Research Process
  60. Market Structure for the Global C reactive protein testing Market
  61. Market Dynamics for the Global C reactive protein testing Market
  62. Global C reactive protein testing Market, Share (%), BY Assay Type, 2022
  63. Global C reactive protein testing Market, Share (%), BY Application, 2022
  64. Global C reactive protein testing Market, Share (%), by Region, 2022
  65. north AMERICA: C REACTIVE PROTEIN TESTING MARKET, SHARE (%), BY REGION, 2022
  66. Europe: C REACTIVE PROTEIN TESTING MARKET, SHARE (%), BY REGION, 2022
  67. Asia-Pacific: C REACTIVE PROTEIN TESTING MARKET, SHARE (%), BY REGION, 2022
  68. Rest of the world: C REACTIVE PROTEIN TESTING MARKET, SHARE (%), BY REGION, 2022
  69. Global C reactive protein testing Market: Company Share Analysis, 2022 (%)
  70. Randox Laboratories Limited: FINANCIAL OVERVIEW SNAPSHOT
  71. Randox Laboratories Limited: SWOT ANALYSIS
  72. MERCK KGAA (MILLIPORE SIGMA): FINANCIAL OVERVIEW SNAPSHOT
  73. MERCK KGAA (MILLIPORE SIGMA): SWOT ANALYSIS
  74. Quest Diagnostics Incorporated: FINANCIAL OVERVIEW SNAPSHOT
  75. Quest Diagnostics Incorporated: SWOT ANALYSIS
  76. Abbott Laboratories: FINANCIAL OVERVIEW SNAPSHOT
  77. Abbott Laboratories: SWOT ANALYSIS
  78. ZOETIS INC. (ABAXIS INC.).: FINANCIAL OVERVIEW SNAPSHOT
  79. ZOETIS INC. (ABAXIS INC.).: SWOT ANALYSIS
  80. Thermo Fisher Scientific: FINANCIAL OVERVIEW SNAPSHOT
  81. Thermo Fisher Scientific: SWOT ANALYSIS
  82. Danaher Corporation (Beckman Coulter Inc.): FINANCIAL OVERVIEW SNAPSHOT
  83. Danaher Corporation (Beckman Coulter Inc.): SWOT ANALYSIS
  84. HORIBA, LTD: FINANCIAL OVERVIEW SNAPSHOT
  85. HORIBA, LTD: SWOT ANALYSIS
  86. F. Hoffmann-La Roche AG: FINANCIAL OVERVIEW SNAPSHOT
  87. F. Hoffmann-La Roche AG: SWOT ANALYSIS
  88. Laboratory Corporation of America Holdings: FINANCIAL OVERVIEW SNAPSHOT
  89. Laboratory Corporation of America Holdings: SWOT ANALYSIS

Market Segmentation

C Reactive Protein Testing Assay Type Outlook (USD Billion, 2018-2032)

  • Enzyme-linked immunosorbent assay (ELISA)
  • Chemiluminescence Immunoassay (CLIA)
  • Immunoturbidimetric assays
  • Others

C Reactive Protein Testing Application Outlook (USD Billion, 2018-2032)

  • Diabetes
  • Rheumatoid Arthritis
  • Cardiovascular Disease
  • Inflammatory Bowel Disease
  • Others

C Reactive Protein Testing Regional Outlook (USD Billion, 2018-2032)

  • North America Outlook (USD Billion, 2018-2032)

    • North America C Reactive Protein Testing by Assay Type
      • Enzyme-linked immunosorbent assay (ELISA)
      • Chemiluminescence Immunoassay (CLIA)
      • Immunoturbidimetric assays
      • Others
    • North America C Reactive Protein Testing by Application
      • Diabetes
      • Rheumatoid Arthritis
      • Cardiovascular Disease
      • Inflammatory Bowel Disease
      • Others

    • US Outlook (USD Billion, 2018-2032)

    • US C Reactive Protein Testing by Assay Type
      • Enzyme-linked immunosorbent assay (ELISA)
      • Chemiluminescence Immunoassay (CLIA)
      • Immunoturbidimetric assays
      • Others
    • US C Reactive Protein Testing by Application
      • Diabetes
      • Rheumatoid Arthritis
      • Cardiovascular Disease
      • Inflammatory Bowel Disease
      • Others

    • CANADA Outlook (USD Billion, 2018-2032)

    • CANADA C Reactive Protein Testing by Assay Type
      • Enzyme-linked immunosorbent assay (ELISA)
      • Chemiluminescence Immunoassay (CLIA)
      • Immunoturbidimetric assays
      • Others
    • CANADA C Reactive Protein Testing by Application
      • Diabetes
      • Rheumatoid Arthritis
      • Cardiovascular Disease
      • Inflammatory Bowel Disease
      • Others

  • Europe Outlook (USD Billion, 2018-2032)

    • Europe C Reactive Protein Testing by Assay Type
      • Enzyme-linked immunosorbent assay (ELISA)
      • Chemiluminescence Immunoassay (CLIA)
      • Immunoturbidimetric assays
      • Others
    • Europe C Reactive Protein Testing by Application
      • Diabetes
      • Rheumatoid Arthritis
      • Cardiovascular Disease
      • Inflammatory Bowel Disease
      • Others

    • Germany Outlook (USD Billion, 2018-2032)

    • Germany C Reactive Protein Testing by Assay Type
      • Enzyme-linked immunosorbent assay (ELISA)
      • Chemiluminescence Immunoassay (CLIA)
      • Immunoturbidimetric assays
      • Others
    • Germany C Reactive Protein Testing by Application
      • Diabetes
      • Rheumatoid Arthritis
      • Cardiovascular Disease
      • Inflammatory Bowel Disease
      • Others

    • France Outlook (USD Billion, 2018-2032)

    • France C Reactive Protein Testing by Assay Type
      • Enzyme-linked immunosorbent assay (ELISA)
      • Chemiluminescence Immunoassay (CLIA)
      • Immunoturbidimetric assays
      • Others
    • France C Reactive Protein Testing by Application
      • Diabetes
      • Rheumatoid Arthritis
      • Cardiovascular Disease
      • Inflammatory Bowel Disease
      • Others

    • UK Outlook (USD Billion, 2018-2032)

    • UK C Reactive Protein Testing by Assay Type
      • Enzyme-linked immunosorbent assay (ELISA)
      • Chemiluminescence Immunoassay (CLIA)
      • Immunoturbidimetric assays
      • Others
    • UK C Reactive Protein Testing by Application
      • Diabetes
      • Rheumatoid Arthritis
      • Cardiovascular Disease
      • Inflammatory Bowel Disease
      • Others

    • ITALY Outlook (USD Billion, 2018-2032)

    • ITALY C Reactive Protein Testing by Assay Type
      • Enzyme-linked immunosorbent assay (ELISA)
      • Chemiluminescence Immunoassay (CLIA)
      • Immunoturbidimetric assays
      • Others
    • ITALY C Reactive Protein Testing by Application
      • Diabetes
      • Rheumatoid Arthritis
      • Cardiovascular Disease
      • Inflammatory Bowel Disease
      • Others

    • SPAIN Outlook (USD Billion, 2018-2032)

    • Spain C Reactive Protein Testing by Assay Type
      • Enzyme-linked immunosorbent assay (ELISA)
      • Chemiluminescence Immunoassay (CLIA)
      • Immunoturbidimetric assays
      • Others
    • Spain C Reactive Protein Testing by Application
      • Diabetes
      • Rheumatoid Arthritis
      • Cardiovascular Disease
      • Inflammatory Bowel Disease
      • Others

    • Rest Of Europe Outlook (USD Billion, 2018-2032)

    • Rest Of Europe C Reactive Protein Testing by Assay Type
      • Enzyme-linked immunosorbent assay (ELISA)
      • Chemiluminescence Immunoassay (CLIA)
      • Immunoturbidimetric assays
      • Others
    • REST OF EUROPE C Reactive Protein Testing by Application
      • Diabetes
      • Rheumatoid Arthritis
      • Cardiovascular Disease
      • Inflammatory Bowel Disease
      • Others

  • Asia-Pacific Outlook (USD Billion, 2018-2032)

    • Asia-Pacific C Reactive Protein Testing by Assay Type
      • Enzyme-linked immunosorbent assay (ELISA)
      • Chemiluminescence Immunoassay (CLIA)
      • Immunoturbidimetric assays
      • Others
    • Asia-Pacific C Reactive Protein Testing by Application
      • Store-Based
      • Non Diabetes
      • Rheumatoid Arthritis
      • Cardiovascular Disease
      • Inflammatory Bowel Disease
      • Others

    • China Outlook (USD Billion, 2018-2032)

    • China C Reactive Protein Testing by Assay Type
      • Enzyme-linked immunosorbent assay (ELISA)
      • Chemiluminescence Immunoassay (CLIA)
      • Immunoturbidimetric assays
      • Others
    • China C Reactive Protein Testing by Application
      • Diabetes
      • Rheumatoid Arthritis
      • Cardiovascular Disease
      • Inflammatory Bowel Disease
      • Others

    • Japan Outlook (USD Billion, 2018-2032)

    • Japan C Reactive Protein Testing by Assay Type
      • Enzyme-linked immunosorbent assay (ELISA)
      • Chemiluminescence Immunoassay (CLIA)
      • Immunoturbidimetric assays
      • Others
    • Japan C Reactive Protein Testing by Application
      • Diabetes
      • Rheumatoid Arthritis
      • Cardiovascular Disease
      • Inflammatory Bowel Disease
      • Others

    • India Outlook (USD Billion, 2018-2032)

    • India C Reactive Protein Testing by Assay Type
      • Enzyme-linked immunosorbent assay (ELISA)
      • Chemiluminescence Immunoassay (CLIA)
      • Immunoturbidimetric assays
      • Others
    • India C Reactive Protein Testing by Application
      • Diabetes
      • Rheumatoid Arthritis
      • Cardiovascular Disease
      • Inflammatory Bowel Disease
      • Others

    • Australia Outlook (USD Billion, 2018-2032)

    • Australia C Reactive Protein Testing by Assay Type
      • Enzyme-linked immunosorbent assay (ELISA)
      • Chemiluminescence Immunoassay (CLIA)
      • Immunoturbidimetric assays
      • Others
    • Australia C Reactive Protein Testing by Application
      • Diabetes
      • Rheumatoid Arthritis
      • Cardiovascular Disease
      • Inflammatory Bowel Disease
      • Others

    • Rest of Asia-Pacific Outlook (USD Billion, 2018-2032)

    • Rest of Asia-Pacific C Reactive Protein Testing by Assay Type
      • Enzyme-linked immunosorbent assay (ELISA)
      • Chemiluminescence Immunoassay (CLIA)
      • Immunoturbidimetric assays
      • Others
    • Rest of Asia-Pacific C Reactive Protein Testing by Application
      • Diabetes
      • Rheumatoid Arthritis
      • Cardiovascular Disease
      • Inflammatory Bowel Disease
      • Others

  • Rest of the World Outlook (USD Billion, 2018-2032)

    • Rest of the World C Reactive Protein Testing by Assay Type
      • Enzyme-linked immunosorbent assay (ELISA)
      • Chemiluminescence Immunoassay (CLIA)
      • Immunoturbidimetric assays
      • Others
    • Rest of the World C Reactive Protein Testing by Application
      • Diabetes
      • Rheumatoid Arthritis
      • Cardiovascular Disease
      • Inflammatory Bowel Disease
      • Others

    • Middle East Outlook (USD Billion, 2018-2032)

    • Middle East C Reactive Protein Testing by Assay Type
      • Enzyme-linked immunosorbent assay (ELISA)
      • Chemiluminescence Immunoassay (CLIA)
      • Immunoturbidimetric assays
      • Others
    • Middle East C Reactive Protein Testing by Application
      • Diabetes
      • Rheumatoid Arthritis
      • Cardiovascular Disease
      • Inflammatory Bowel Disease
      • Others

    • Africa Outlook (USD Billion, 2018-2032)

    • Africa C Reactive Protein Testing by Assay Type
      • Enzyme-linked immunosorbent assay (ELISA)
      • Chemiluminescence Immunoassay (CLIA)
      • Immunoturbidimetric assays
      • Others
    • Africa C Reactive Protein Testing by Application
      • Diabetes
      • Rheumatoid Arthritis
      • Cardiovascular Disease
      • Inflammatory Bowel Disease
      • Others

    • Latin America Outlook (USD Billion, 2018-2032)

    • Latin America C Reactive Protein Testing by Assay Type
      • Enzyme-linked immunosorbent assay (ELISA)
      • Chemiluminescence Immunoassay (CLIA)
      • Immunoturbidimetric assays
      • Others
    • Latin America C Reactive Protein Testing by Application
      • Diabetes
      • Rheumatoid Arthritis
      • Cardiovascular Disease
      • Inflammatory Bowel Disease
      • Others
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Related Reports

Regional Reports
Country Reports

Customer Strories

Customer Stories
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓